Blog post by Bill Claxton.
Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.
“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).
“This is the evidence we’ve been waiting for”
Not only does the NETTER1 trial result demonstrate that PRRT is the 2nd most effective treatment for mid-gut neuroendocrine tumor patients with SST receptors (after surgery) it can potentially move PRRT to a 2nd-line therapy, to begin right after surgical removal of the primary (with SST analogs used for anti-proliferative maintenance thereafter). These results will lead to changes in practice for functional mid-gut NETs, launch confirmatory studies for lung and hind-gut NET patients and provide a big boost to nuclear medicine programes worldwide!
No less significant, the RADIANT4 trial results
No less significant, there was an announcement of the RADIANT4 trial results by Dr James C. Yao, chair of the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, USA. The study concluded that: “Treatment with everolimus was associated with a 52% improvement in median progression-free survival (PFS) compared with placebo in patients with advanced nonfunctional lung and gastrointestinal (GI) neuroendocrine tumors (NETs)”.
Medical abstract is here (www.europeancancercongress.org/Scientific-Programme) and a press release is here (www.onclive.com/conference-coverage).
The International Neuroendocrine Cancer Alliance’s Blog.